Series A14 October 2020

Ori Biotech raises £23.2m in Series A funding led by Northpond Ventures and Octopus Ventures

The Series A round was led by Northpond Ventures and Octopus Ventures to help bring the company manufacturing platform to market.

£23.2MSeries A

Ori Biotech develops advanced manufacturing technology designed to automate and standardise cell and gene therapy production. The firm works to help developers bring treatments to market at scale.

Ori Biotech has secured £23.2m in a Series A funding round led by Northpond Ventures and Octopus Ventures. The round also drew participation from existing backers including Amadeus Capital Partners, Delin Ventures, and Kindred Capital. The capital will be used to bring the company manufacturing platform to market and advance its technology into clinical settings.

The financing follows previous backing and brings the total capital raised by the company to date to £31.6m. Ori Biotech aims to address longstanding manufacturing bottlenecks in the cell and gene therapy sector through automation and standardisation.

From the founder

"Closing a significant Series A round, during these uncertain times, further validates Ori’s disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality, and decrease costs,"

Jason Foster

CEO at Ori Biotech

Investor perspective

"As early investors in disruptive life sciences platform technology companies, we have seen how cutting-edge technologies like Ori’s can bring significant value to the industry and lead to breakthroughs for patients,"